Parabilis Medicines Appoints Alan M. Sebulsky to Board of Directors
Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing innovative therapies through its proprietary Helicon™ peptide platform, has announced the appointment of veteran biopharmaceutical finance executive Alan M. Sebulsky to its Board of Directors.
The company stated that Sebulsky brings extensive expertise in biotechnology investment, strategic portfolio management, financial analysis, and corporate growth, strengthening Parabilis’ leadership as it advances its pipeline of cancer therapies targeting historically difficult-to-drug proteins.
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer, and President of Parabilis Medicines, welcomed the appointment and highlighted Sebulsky’s broad industry experience. According to Mammen, Sebulsky’s background as both a leading biotechnology equity analyst and an experienced public markets investor provides the company with valuable insight into scientific evaluation, capital allocation, and long-term value creation.
Sebulsky has spent more than four decades in the biopharmaceutical and healthcare investment sectors. Most recently, he served as Partner and Portfolio Manager at Adage Capital Management, where he managed a diversified biopharmaceutical investment portfolio valued at more than $2 billion. During his tenure, he led investment strategies focused on identifying high-potential healthcare and biotechnology companies across multiple therapeutic areas.
Before joining Adage Capital Management, Sebulsky founded Apothecary Capital, a healthcare-focused investment management firm specializing in opportunities within the pharmaceutical, biotechnology, and healthcare industries. Through Apothecary Capital, he developed deep expertise in evaluating emerging healthcare technologies, clinical-stage companies, and innovative therapeutic platforms.
Throughout his career, Sebulsky has also played a significant role in corporate governance and strategic oversight. He previously served on the Boards of Directors and Audit Committees of Jazz Pharmaceuticals and Arrow International, both publicly traded healthcare companies. In addition, he contributed to the boards of several privately held healthcare companies backed by Apothecary Capital investments. His board-level experience includes supporting executive teams on business strategy, commercial planning, portfolio prioritization, and financial management.
Sebulsky earned both his Master of Science degree in finance and his Bachelor of Business Administration degree in finance and economics from the University of Wisconsin–Madison.
Parabilis Medicines is focused on creating therapies for high-impact disease targets that have traditionally been considered undruggable using conventional treatment approaches. The company combines proprietary research data, laboratory technologies, artificial intelligence, and physics-based computational methods to develop Helicons™ — a new class of stabilized, cell-penetrating alpha-helical peptides designed to access intracellular protein targets that are difficult for traditional drugs to reach.
The company’s research efforts are primarily concentrated in oncology, with programs targeting both rare and common cancers. Its lead investigational therapy, zolucatetide, formerly known as FOG-001, is designed to directly inhibit the interaction between β-catenin and T-cell factor transcription proteins. This pathway has been linked to colorectal cancer, desmoid tumors, and other cancers driven by abnormal Wnt/β-catenin signaling.
In addition to zolucatetide, Parabilis is advancing multiple investigational prostate cancer programs, including ERG degraders and allosteric ARON therapies, while continuing to expand its broader preclinical oncology pipeline.
The appointment of Sebulsky comes as Parabilis continues to strengthen its leadership team and strategic capabilities to support future clinical development, pipeline expansion, and long-term corporate growth initiatives.
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. Leveraging over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms, the company has developed a new class of stabilized, cell-penetrant alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.
Headquartered in Cambridge, Mass., Parabilis is advancing a focused pipeline of therapies across both rare and common cancers. Its lead candidate, zolucatetide (previously known as FOG-001), is the first direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors, implicated in colorectal cancer, desmoid tumors, and a range of other Wnt/β-catenin-driven tumors. Parabilis is also advancing investigational degraders of ERG and allosteric ARON for the treatment of prostate cancer, as well as other preclinical programs.
